Recent data from the Hong Kong Stock Exchange reveals that on June 17th, JPMorgan Chase acquired an additional 1,068,875 shares of INNOVENT BIO (01801) at a price of HK$75.3978 per share. The total consideration for this transaction amounted to approximately HK$80.59 million.
Following this purchase, JPMorgan Chase's total holding in the company has risen to around 87.20 million shares. This represents a stake of 5.01% in the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments